文献速递消化道肿瘤与早癌消化内镜

基于定量粪便免疫化学检测的预测模型可对结直肠癌筛查项目中的结直肠癌风险进行分层

A Predictive Model Based on Quantitative Fecal Immunochemical Test Can Stratify the Risk of Colorectal Cancer in an Organized Screening Program.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-11-19

研究基于2004至2019年粪便免疫化学检测(FIT)阳性(≥20 μg血红蛋白/g粪便)后接受结肠镜检查的筛查人群,建立并验证了结直肠癌风险预测模型。模型纳入年龄≥70岁、男性、粪便血红蛋白水平及首轮FIT等变量,验证队列曲线下面积为0.75,应用模型可大幅减少延迟诊断的结直肠癌。

要点

  • FIT阳性人群中,年龄≥70岁、男性、粪便血红蛋白升高及首轮FIT与结直肠癌独立相关。
  • 预测模型验证队列曲线下面积为0.75(95%CI 0.73-0.77),区分能力良好。
  • 应用该模型在多种及时结肠镜安排情景下可使延迟诊断的结直肠癌减少超过三分之二。

核心结论

  • 研究在大型结直肠癌筛查队列中建立并验证了FIT阳性患者风险分层的预测模型,应用该模型有助于政策制定者按结直肠癌风险确定FIT阳性个体的优先次序,大幅降低延迟诊断率。

研究设计与样本

  • 研究为在2004至2019年间FIT阳性(≥20 μg血红蛋白/g粪便,OC-sensor)后接受结肠镜检查的筛查队列中推导并验证基于逻辑回归的预测模型,共纳入40276例患者(女性46%,平均年龄66±4岁)。

主要发现

  • 与结直肠癌独立相关的变量包括年龄≥70岁(OR 1.20,95%CI 1.03-1.40)、男性(OR 1.23,95%CI 1.11-1.37)、粪便血红蛋白50-199 μg/g(OR 2.84,95%CI 2.47-3.27)及≥200 μg/g(OR 6.91,95%CI 5.99-7.98)、首轮FIT(OR 1.53,95%CI 1.35-1.73)。
  • 模型在验证队列中的区分能力良好,受试者工作特征曲线下面积为0.75(95%CI 0.73-0.77)。
  • 在多种FIT阳性后及时结肠镜安排情景下,应用该模型可使延迟诊断的结直肠癌减少超过三分之二。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A significant number of post fecal immunochemical test (FIT) colonoscopies in European-organized colorectal cancer (CRC) screening programs are performed beyond the recommended 31-day threshold due to overburdened colonoscopy services. We aimed to develop a simple predictive model to stratify CRC risk of FIT+ patients. METHODS: In a cohort of screenees undergoing colonoscopy following a positive (≥20 μg hemoglobin/g feces) OC-sensor FIT result between 2004 and 2019, we derived and validated logistic regression-based models including variables independently associated with CRC and advanced neoplasms. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported. RESULTS: Overall, 40,276 patients (46% female; mean age, 66 ± 4 years) undergoing post FIT colonoscopy were included. Variables independently associated with CRC were age ≥70 years (OR, 1.20; 95% CI, 1.03-1.40), male sex (OR, 1.23; 95% CI, 1.11-1.37), fecal hemoglobin level (50-199 μg/g: OR, 2.84; 95% CI, 2.47-3.27; ≥200 μg/g: OR, 6.91; 95% CI, 5.99-7.98), and first round of FIT (OR, 1.53; 95% CI, 1.35-1.73). The discriminative ability of the model was good (area under the receiver operating characteristic, 0.75; 95% CI, 0.73-0.77) in the validation cohort. Applying the model would lead to over two-thirds decrease in delayed CRC diagnoses, considering various scenarios of timely colonoscopy scheduling after FIT+. CONCLUSIONS: We derived and validated a predictive model for risk stratification of patients with positive FIT in a large CRC screening cohort. Applying our model in screening practice would allow policy makers to effectively prioritize FIT+ individuals based on the risk of CRC, substantially reducing the rate of delayed CRC diagnosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Frazzoni L, Pecere S, Hassan C, et al. A Predictive Model Based on Quantitative Fecal Immunochemical Test Can Stratify the Risk of Colorectal Cancer in an Organized Screening Program. Clin Gastroenterol Hepatol. 2024. PMID: 39566566. doi:10.1016/j.cgh.2024.09.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。